Mechanism of Cyclophilin A in tumor

doi:10.3760/cma.j.issn.1673-422X.2016.06.010

Abstract

Abstract: Cyclophilin A (CypA) is found to be highly expressed in different kinds of tumor cells, which could regulate the occurrence and development of many kinds of tumor through multiple signal transduction pathways such as inducing the formation of inflammatory carcinoma, accelerating the transcription cycle of tumor cells, promoting the invasion and metastasis of tumor cells, inhibiting the apoptosis of tumor cells and reducing the sensitivity of tumor cells to chemotherapy drugs. It suggests that CypA might be considered as a kind of oncogene, which is expected to be a novel target for tumor treatment.

Key words: Neoplasms, Cyclophilin A, Molecular mechanisms of pharmacological action

Lu Kaiqiang, Zhou Zhigang, Tian Wen, Zou Zhinan, Liao Caiqin, Xie Feiyan, Tu Jian. Mechanism of Cyclophilin A in tumor[J]. Journal of International Oncology, 2016, 43(6): 439-441.

References

［1］ Sun S, Wang Q, Giang A, et al. Knockdown of CypA inhibits interleukin，8 (IL，8) and IL8mediated proliferation and tumor growth of glioblastoma cells through downregulated NFκB［J］. J Neurooncol, 2011, 101(1): 1，14. DOI: 10.1007/s11060，010，0220，y. ［2］ Sun S, Guo M, Zhang JB, et al. Cyclophilin A (CypA) interacts with NFκB subunit, p65/RelA, and contributes to NFκB activation signaling［J］. PLoS One, 2014, 9(8): e96211. DOI: 10.1371/journal.pone. ［3］ Benarafa C. Tumorinduced inflammation alters neutrophil phenotype and disease progression［J］. Breast Cancer Res, 2015, 17(1): 135. DOI: 10.1186/s13058-015-0644-6. ［4］ Simon PS, Sharman SK, Lu C, et al. The NFκB p65 and p50 homodimer cooperate with IRF8 to activate iNOS transcription［J］. BMC Cancer, 2015, 15: 770. DOI: 10.1186/s12885-015-1808-6. ［5］ Obchoei S, Sawanyawisuth K, Wongkham C, et al. Secreted cyclophilin A mediates G1/S phase transition of cholangiocarcinoma cells via CD147/ERK1/2 pathway［J］. Tumour Biol, 2015, 36(2): 849-859. DOI: 10.1007/s13277-014-2691-5. ［6］ Gelbert LM, Cai S, Lin X, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: invivo cell cycledependent/independent antitumor activities alone/in combination with gemcitabine［J］. Invest New Drugs, 2014, 32(5): 825-837. DOI: 10.1007/s10637-014-0120-7. ［7］ Dong P, Maddali MV, Srimani JK, et al. Division of labour between Myc and G1 cyclins in cell cycle commitment and pace control［J］. Nat Commun, 2014, 5: 475. DOI: 10.1038/ncomms5750. ［8］ Syed F, Rycyzyn MA, Westgate L, et al. A novel and functional interaction between cyclophilin A and prolactin receptor［J］. Endocrine, 2003, 20(12): 83-90. ［9］ Alkharusi A, Lesma E, Ancona S, et al. Role of prolactin receptors in lymphangioleiomyomatosis［J］. PLoS One, 2016, 11(1): e0146653. DOI: 10.1371/journal.pone.0146653. ［10］ Asher JM, O′Leary KA, Rugowski DE, et al. Prolactin promotes mammary pathogenesis independently from cyclinD1［J］. Am J Pathol, 2012, 181(1): 294302. DOI: 10.1016/j.ajpath.2012.03.041. ［11］ Tang Y, Lv P, Sun Z, et al. 1433β promotes migration and invasion of human hepatocellular carcinoma cells by modulating expression of MMP2 and MMP9 through PI3K/Akt/NFκB pathway［J］. PLoS One, 2016, 11(1): e0146070. DOI: 10.1371/journal.pone.0146070. ［12］ Takahashi M, Suzuki S, Ishikawa K. Cyclophilin AEMMPRIN interaction induces invasion of head and neck squamous cell carcinoma［J］. Oncol Rep, 2012, 27(1): 198203. DOI: 10.3892/or.2011.1474. ［13］ Xu T, Zhou M, Peng L, et al. Upregulation of CD147 promotes cell invasion, epithelialtomesenchymal transition and activates MAPK/ERK signaling pathway in colorectal cancer［J］. Int J Clin Exp Pathol, 2014, 7(11): 7432-7441. ［14］ Gravina GL, Mancini A, Muzi P, et al. CXCR4 pharmacological inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models［J］. Prostate, 2015, 75(12): 1227-1246. DOI: 10.1002/pros.23007. ［15］张涓娟, 蒲宇, 李勇, 等. PI3K/AKT和MAPK/ERK1/2信号通路对胰腺癌PANC1细胞VEGF表达的影响［J］. 川北医学院学报, 2014, 29(1): 44-48. DOI: 10.3969/J.ISSN.1005-3697.2014.01.09. ［16］ Huang C, Sun Z, Sun Y, et al. Association of increased ligand cyclophilin A and receptor CD147 with hypoxia, angiogenesis, metastasis and prognosis of tongue squamous cell carcinoma［J］. Histopathology, 2012, 60(5): 793803. DOI: 10.1111/j.13652559.2011.04130.x. ［17］ Li J, Peng L, Wu L, et al. Depletion of CD147 sensitizes human malignant melanoma cells to hydrogen peroxideinduced oxidative［J］. J Dermatol Sci, 2010, 58(3): 204-210. DOI: 10.1016/j.jdermsci.2010.03.022. ［18］ Kim H, Oh Y, Kim K, et al. Cyclophilin A regulates JNK/p38MAPK signaling through its physical interaction with ASK1［J］. Biochem Biophys Res Commun, 2015, 464(1): 112-117. DOI: 10.1016/j.bbrc.2015.06.078. ［19］ Jiang Q, Yuan Y, Zhou J, et al. Apoptotic events induced by high glucose in human hepatoma HepG2 cells involve endoplasmic reticulum stress and MAPK′s activation［J］. Mol Cell Biochem, 2015, 399(1-2): 113-122. DOI: 10.1007/s11010-014-2238-5. ［20］ Cheng YX, Liu R, Wang Q, et al. Realgarinduced apoptosis of cervical cancer cell line Siha via cytochrome c release andcaspase3 and caspase9 activation［J］. Chin J Integr Med, 2012, 18(5): 359-365. DOI: 10.1007/s11655-011-0697-z. ［21］刘凤华. CypA对胰腺癌生物学行为的影响及机制研究［D］. 天津: 天津医科大学, 2012. ［22］ Huang Q, Li J, Xing J, et al. CD147 promotes reprogramming of glucose metabolism and cell proliferation in HCC cells by inhibiting the p53dependent signaling pathway［J］. J Hepatol, 2014, 61(4): 859866. DOI: 10.1016/j.jhep.2014.04.035. ［23］ Han X, Yoon SH, Ding Y, et al. Cyclosporin A and sanglifehrin A enhance chemotherapeutic effect of cisplatin in C6 glioma cells［J］. Oncol Rep, 2010, 23(4): 1053-1062. ［24］ Hamilton G. Cyclophilin A as a target of cisplatin chemosensitizers［J］. Curr Cancer Drug Targets, 2014, 14(1): 46-58. ［25］ Xie ZY, Lv K, Xiong Y, et al. ABCG2meditated multidrug resistance and tumorinitiating capacity of side population cells from colon cancer［J］. Oncol Res Treat, 2014, 37(11): 666-668, 670-672. DOI: 10.1159/000368842.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.